1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC

Dall’Olio, Filippo Gustavo; Garcia, Camilo; Bettaı̈eb, Ali; Naigeon, Marie; Facchinetti, Fabio; Danlos, F-X.; Caramella, Caroline; Benítez, José Carlos; Aldea, Mihaela; Blanc‐Durand, Félix; Naltet, Charles; Abdayem, Pamela; Lavaud, Pernelle; Ghigna, Maria-Rosa; Chaput, Nathalie; Marabelle, Aurélien; Planchard, David; Soria, J-C.; Besse, Benjamin

doi:10.1016/j.annonc.2021.08.1896

Search citation statements

Order By: Relevance

Paper Sections

Select...

Host-related Biomarkers1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High lactate dehydrogenase (LDH) is associated with an adverse prognosis in many solid tumors [ 92 ], and the same is true for immunotherapy patients [ 93 ]. Using the same principle of glycolysis of tumor cells, in patients receiving pembrolizumab monotherapy, PET-derived parameters (such as total glycolysis of the lesion and tumor metabolic volume) are related to the prognosis of the patients [ 94 ]. Systemic inflammation suggested by elevated CRP is a very strong indicator of poor prognosis for patients receiving immunity therapy and has potential negative predictive value [ 95 ].…”

Section: Host-related Biomarkersmentioning

confidence: 99%

The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

Pan

Zeng

et al. 2022

Biomark Res

View full text Add to dashboard Cite

Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although these indicators have a certain predictive effect, their predictive performance is not good. Therefore, clinicians must make adjustments to recognize markers. This is a review article that summarized immunotherapeutic biomarkers according to the “seed-soil-environment”, generalizes primary resistance to immunotherapy, and summarizes the integration of markers.

show abstract